参考文献/References:
[1] Levine GN,Bates ER,Bittl JA,et al. 2016 ACC/AHA guideline focused?update on duration of dual?antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association Task?Force?on?clinical practice guidelines[J]. J Am Coll Cardiol,2016,68(10):1082-1115.
[2] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC) and of the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2018,39(3):213-260.
[3] Subherwal S,Bach RG,Chen AY,et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE(Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score[J]. Circulation,2009,119(14):1873-1882.
[4] Mehran R,Pocock SJ,Nikolsky E,et al. A risk score to predict bleeding in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2010,55(23):2556-2566.
[5] Baber U,Mehran R,Giustino G,et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents:risk scores from PARIS[J]. J Am Coll Cardiol,2016,67(19):2224-2234.
[6] Costa F,van Klaveren D,James S,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT) score:a pooled analysis of individual-patient datasets from clinical trials[J]. Lancet,2017,389(10073):1025-1034.
[7] Flores-Ríos X,Couto-Mallón D,Rodríguez-Garrido J, et al. Comparison of the performance of the CRUSADE,ACUITY-HORIZONS,and ACTION bleeding risk scores in STEMI undergoing primary PCI:insights from a cohort of 1391 patients[J]. Eur Heart J Acute Cardiovasc Care,2013,2(1):19-26.
[8] Liu R,Zheng W,Zhao G,et al. Predictive validity of CRUSADE,ACTION and ACUITY-HORIZONS bleeding risk scores in Chinese patients with ST-segment elevation myocardial infarction[J]. Circ J,2018,82(3):791-797.
[9] O’Gara PT,Kushner FG,Ascheim DD,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2013,127(4):529-555.
[10]Xi S,Zhou S,Wang X,et al. The performance of CRUSADE and ACUITY bleeding risk scores in ticagrelor-treated ACS patients who underwent PCI[J]. Thromb Haemost,2017,117(11):2186-2193.
[11]Manzano-Fernández S,Sánchez-Martínez M,Flores-Blanco PJ,et al. Comparison of the global registry of acute coronary events risk score versus the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines risk score to predict in-hospital mortality and major bleeding in acute coronary syndromes[J]. Am J Cardiol,2016,117(7):1047-1054.
[12]Chen TY,Chung WJ,Lee CH,et al. Evaluation of bleeding risk in patients with acute myocardial infarction undergoing transradial percutaneous coronary intervention[J]. Int Heart J,2019,60(3):577-585.
[13]Zhao XY,Li JX,Tang XF,et al. Evaluation of the patterns of non-adherence to anti-platelet regimens in stented patients bleeding score for predicting the long-term out-of-hospital bleeding risk in Chinese patients after percutaneous coronary intervention[J]. Chin Med J(Engl),2018,131(12):1406-1411.
[14]Marquis-Gravel G,Neely ML,Valgimigli M,et al. Long-term bleeding risk prediction with dual antiplatelet therapy after acute coronary syndromes treated without revascularization[J]. Circ Cardiovasc Qual Outcomes,2020,13(9):e006582.
[15]赵雪燕,杨进刚,范肖雪,等. PARIS 出血评分对急性心肌梗死药物支架术后患者院内出血的预测价值——中国急性心肌梗死注册研究[J].中国循环杂志,2018,33(2):110-116.
[16]Capodanno D,Huber K,Mehran R,et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing?PCI:JACC state-of-the-art review[J]. J Am Coll Cardiol,2019,74(1):83-99.
[17]Yoshida R,Ishii H,Morishima I,et al. Performance of HAS-BLED,ORBIT,PRECISE-DAPT,and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention[J]. J Cardiol,2019,73(6):479-487.
[18]Choi KH,Song YB,Lee JM,et al. Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention:an analysis from the SMART-DATE RANDOMIZED TRIAL[J]. Circ Cardiovasc Interv,2020,13(5):e008530.
[19]Pavasini R,Maietti E,Tonet E,et al. Bleeding risk scores and scales of frailty for the prediction of haemorrhagic events in older adults with acute coronary syndrome:insights from the FRASER study[J]. Cardiovasc Drugs Ther,2019,33(5):523-532.
[20]Guerrero C,Ariza-Solé A,Formiga F,et al. Applicability of the PRECISE-DAPT score in elderly patients with myocardial infarction[J]. J Geriatr Cardiol,2018,15(12):713-717.
[21]Tanik VO,Cinar T,Arugaslan E,et al. The predictive value of PRECISE-DAPT score for in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Angiology,2019,70(5):440-447.
[22]Ando T,Nakazato K,Kimishima Y,et al. The clinical value of the PRECISE-DAPT score in predicting long-term prognosis in patients with acute myocardial infarction[J]. Int J Cardiol Heart Vasc,2020,29:100552.
[23]??nar T,Tan?k VO,Aru?aslan E,et al. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention [J]. Cardiovasc Interv Ther,2019,34(3):207-215.
[24]Yildirim E,Turkkan O,Czcan KS,et al. The predictive value of PRECISE-DAPT score for arrhythmic complications in patients with ST-elevation myocardial infarction [J]. Coron Artery Dis,2019,30(7):499-504.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(7):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(7):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(7):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(7):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]